Literature DB >> 19952427

Examination of the expression of cyclooxygenase-2 in placenta villi from sufferers of pregnancy induced hypertension.

Masaki Okawara1, Hiroyuki Seki, Kikumi Matsuoka, Fumie Hashimoto, Hidenori Hayashi, Satoru Takeda.   

Abstract

OBJECTIVES: The purpose of this paper is to elucidate the roles of phospholipase A(2) (PLA(2)), cyclooxygenase-2 (COX-2), and prostaglandin I(2) (PGI(2)) synthase in pregnancy induced hypertension (PIH).
METHODS: In placentas from normal pregnant women and pregnant women with severe PIH, the enzyme expression of PLA(2), COX-2, and PGI(2) synthase was measured using real time reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: The expression of each enzyme was compared between normal (n=12) and PIH (n=12) groups. The expression levels of COX-2 and PGI(2) synthase during PIH pregnancy were significantly decreased to about 51% and 68%, respectively, of their values in normal pregnancy. However, the expression of PLA(2) was hardly changed by PIH.
CONCLUSIONS: The decreases in COX-2 and PGI(2) synthase expression in severe PIH placentas may be causal factors in the disruption of the PGI(2)-thromboxane A(2) (TXA(2)) balance in favor of TXA(2). The decrease in COX-2 was more marked than that of PGI(2) synthase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952427     DOI: 10.1248/bpb.32.2053

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Molecular Changes on Maternal-Fetal Interface in Placental Abruption-A Systematic Review.

Authors:  Monika Bączkowska; Magdalena Zgliczyńska; Jan Faryna; Ewa Przytuła; Błażej Nowakowski; Michał Ciebiera
Journal:  Int J Mol Sci       Date:  2021-06-21       Impact factor: 5.923

2.  Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy.

Authors:  Yan-Shan Chen; Ling Shen; Rui-Qin Mai; Ying Wang
Journal:  Exp Ther Med       Date:  2014-09-02       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.